PCN77 Cost Effectiveness Analysis in the Veneto Region of Nab-Paclitaxel Monotherapy II Line Versus Conventional Paclitaxel in Patients With Breast Cancer and for Whom Anthracyclines are Not Indicated
P.R. Maran, A. Aiello, M.R. Magrì, C. Alberti, E. Visentin, F. Venturini, G. ScroccaroVolume:
15
Year:
2012
Language:
english
DOI:
10.1016/j.jval.2012.08.2117
File:
PDF, 61 KB
english, 2012